News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
692,411 Results
Type
Article (39889)
Company Profile (329)
Press Release (652193)
Section
Business (206718)
Career Advice (2049)
Deals (35806)
Drug Delivery (87)
Drug Development (82096)
Employer Resources (172)
FDA (16154)
Job Trends (15110)
News (349352)
Policy (32754)
Tag
Academia (2550)
Alliances (49831)
Alzheimer's disease (1236)
Approvals (16072)
Artificial intelligence (117)
Bankruptcy (355)
Best Places to Work (11574)
Biotechnology (234)
Breast cancer (102)
Cancer (894)
Career advice (1707)
Cell therapy (197)
Clinical research (64922)
Collaboration (323)
Compensation (160)
COVID-19 (2543)
Cystic fibrosis (79)
Data (840)
Diabetes (128)
Diagnostics (6110)
Drug pricing (78)
Earnings (85113)
Employer resources (150)
Events (111133)
Executive appointments (245)
FDA (16589)
Funding (287)
Gene therapy (149)
GLP-1 (578)
Government (4356)
Healthcare (18728)
Infectious disease (2616)
Inflammatory bowel disease (103)
Interviews (325)
IPO (16495)
Job creations (3829)
Job search strategy (1462)
Layoffs (421)
Legal (7896)
Lung cancer (154)
Manufacturing (152)
Medical device (13156)
Medtech (13161)
Mergers & acquisitions (19316)
Metabolic disorders (355)
Neuroscience (1479)
NextGen Class of 2024 (6552)
Non-profit (4481)
Northern California (1182)
Obesity (211)
Opinion (192)
Patents (94)
People (56949)
Phase I (20176)
Phase II (28643)
Phase III (21274)
Pipeline (203)
Postmarket research (2563)
Preclinical (8570)
Radiopharmaceuticals (244)
Rare diseases (179)
Real estate (6011)
Regulatory (21677)
Research institute (2330)
Resumes & cover letters (354)
Southern California (1070)
Startups (3642)
United States (11597)
Vaccines (545)
Weight loss (162)
Date
Last 7 days (779)
Last 30 days (2664)
Last 365 days (36104)
2024 (30565)
2023 (40659)
2022 (51785)
2021 (56341)
2020 (54540)
2019 (46983)
2018 (35386)
2017 (32636)
2016 (32060)
2015 (38110)
2014 (32005)
2013 (26893)
2012 (29013)
2011 (29668)
2010 (27706)
Location
Africa (736)
Arizona (188)
Asia (38281)
Australia (6174)
California (2690)
Canada (1167)
China (212)
Colorado (117)
Connecticut (121)
Europe (82409)
Florida (388)
Georgia (98)
Illinois (309)
Indiana (177)
Kansas (95)
Maryland (517)
Massachusetts (2207)
Michigan (142)
Minnesota (248)
New Jersey (813)
New York (830)
North Carolina (700)
Northern California (1182)
Ohio (124)
Pennsylvania (741)
South America (1116)
Southern California (1070)
Texas (380)
Utah (77)
Washington State (321)
692,411 Results for "kinnate biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
XOMA Corporation entered into a merger agreement to acquire Kinnate Biopharma Inc. for a base cash price per share of Kinnate common stock of $2.3352 per share and an additional cash amount of not more than $0.2527 per share.
March 19, 2024
·
8 min read
Business
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.
March 1, 2024
·
10 min read
Deals
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
Kinnate Biopharma Inc. announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate for a price per share of Kinnate common stock of between $2.3352 and $2.5879 in cash, consisting of a base cash price of $2.3352 per share and an additional cash amount of up to $0.2527 per share.
February 16, 2024
·
7 min read
Business
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the third quarter of 2023 and recent corporate updates.
November 9, 2023
·
9 min read
Biotech Bay
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.
September 18, 2023
·
13 min read
Biotech Bay
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories - March 1, 2024
Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
March 1, 2024
·
8 min read
Deals
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
XOMA Corporation announced it has entered an agreement to acquire Kinnate Biopharma Inc. for a base cash price of $2.3352 per share and an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a non-transferable contingent value right.
February 16, 2024
·
6 min read
Business
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the second quarter of 2023 and recent corporate updates.
August 8, 2023
·
9 min read
Biotech Bay
Kinnate Biopharma Inc. to Participate in Upcoming June 2023 Investor Conferences
Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced that the company will participate in two upcoming investor conferences.
June 1, 2023
·
2 min read
Business
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates
Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the first quarter of 2023 and recent corporate updates.
May 11, 2023
·
9 min read
1 of 69,242
Next